DK1075258T3 - Hidtil ukendte fedtsyreanaloger til behandling af adipositas - Google Patents

Hidtil ukendte fedtsyreanaloger til behandling af adipositas

Info

Publication number
DK1075258T3
DK1075258T3 DK99933292T DK99933292T DK1075258T3 DK 1075258 T3 DK1075258 T3 DK 1075258T3 DK 99933292 T DK99933292 T DK 99933292T DK 99933292 T DK99933292 T DK 99933292T DK 1075258 T3 DK1075258 T3 DK 1075258T3
Authority
DK
Denmark
Prior art keywords
sub
treatment
fatty acid
obesity
acid analogues
Prior art date
Application number
DK99933292T
Other languages
English (en)
Inventor
Rolf Berge
Original Assignee
Thia Medica As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thia Medica As filed Critical Thia Medica As
Application granted granted Critical
Publication of DK1075258T3 publication Critical patent/DK1075258T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
DK99933292T 1998-05-08 1999-04-23 Hidtil ukendte fedtsyreanaloger til behandling af adipositas DK1075258T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/NO1998/000143 WO1999058120A1 (en) 1998-05-08 1998-05-08 USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
PCT/NO1999/000135 WO1999058121A1 (en) 1998-05-08 1999-04-23 Novel fatty analogues for the treatment of obesity, hypertension and fatty liver

Publications (1)

Publication Number Publication Date
DK1075258T3 true DK1075258T3 (da) 2003-12-01

Family

ID=19907879

Family Applications (3)

Application Number Title Priority Date Filing Date
DK99933292T DK1075258T3 (da) 1998-05-08 1999-04-23 Hidtil ukendte fedtsyreanaloger til behandling af adipositas
DK99933293T DK1075259T3 (da) 1998-05-08 1999-04-23 Hidtil ukendte fedtsyreanaloger til behandling af diabetes
DK99940723T DK1075260T3 (da) 1998-05-08 1999-05-07 Hidtil ukendte fedtsyreanaloger til behandling af sekundær restenose

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK99933293T DK1075259T3 (da) 1998-05-08 1999-04-23 Hidtil ukendte fedtsyreanaloger til behandling af diabetes
DK99940723T DK1075260T3 (da) 1998-05-08 1999-05-07 Hidtil ukendte fedtsyreanaloger til behandling af sekundær restenose

Country Status (18)

Country Link
US (4) US6365628B1 (da)
EP (5) EP1075258B1 (da)
JP (3) JP2002514595A (da)
KR (3) KR100701503B1 (da)
CN (3) CN1223343C (da)
AT (5) ATE245416T1 (da)
AU (4) AU7240398A (da)
BR (2) BR9910297A (da)
CA (3) CA2331408C (da)
DE (5) DE69932864D1 (da)
DK (3) DK1075258T3 (da)
ES (3) ES2207253T3 (da)
HK (3) HK1034912A1 (da)
NO (3) NO20005463L (da)
NZ (3) NZ508047A (da)
PT (2) PT1075259E (da)
RU (3) RU2221558C2 (da)
WO (4) WO1999058120A1 (da)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058120A1 (en) * 1998-05-08 1999-11-18 Rolf Berge USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
AUPQ291499A0 (en) * 1999-09-17 1999-10-07 Women's And Children's Hospital Adelaide Novel nitro and sulphur containing compounds
AU784588B2 (en) * 1999-09-17 2006-05-04 Peplin Biolipids Pty Ltd Anti-inflammatory nitro- and thia- fatty acids
AU784123B2 (en) * 1999-10-13 2006-02-09 Marco A. Chacon Therapeutic intervention to mimic the effect of caloric restriction
NO328803B1 (no) 2000-03-03 2010-05-18 Thia Medica Nye fettsyreanaloger
NO20003591L (no) * 2000-07-13 2002-01-14 Thia Medica As Fettsyreanaloger for behandling av kreft
NO20006008L (no) 2000-11-28 2002-05-29 Thia Medica As Fettsyreanaloger for behandling av inflammatoriske og autoimmune sykdommer
DE10115740A1 (de) * 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
IL142536A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Carriers for therapeutic preparations for treatment of t-cell mediated diseases
IL142535A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
US6908632B1 (en) 2002-04-19 2005-06-21 Pharmanex, Llc Blood glucose modulating compositions and methods
DK1547614T3 (da) * 2002-05-28 2011-04-04 Ajinomoto Kk Medicinsk sammensætning til inhibering af ekspressionen af ATP-citrat-lyase og anvendelse deraf
JP5008258B2 (ja) 2002-06-20 2012-08-22 アイシー・ベック・リミテッド 含硫黄ホスホリピド誘導体
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US20040220190A1 (en) * 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US7045547B2 (en) * 2002-08-20 2006-05-16 University Of Delaware Acyl-CoA dehydrogenase allenic inhibitors
RU2005106274A (ru) 2002-09-06 2005-11-10 Янссен Фармацевтика, Н.В. (Be) Гетероциклические соединения
US20040092590A1 (en) * 2002-09-27 2004-05-13 Linda Arterburn Glycemic control for prediabetes and/or diabetes Type II using docosahexaenoic acid
CA2501318A1 (en) * 2002-10-10 2004-04-22 Yeda Research And Development Co. Ltd Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents
FR2850650B1 (fr) * 2003-01-31 2005-03-25 Genfit S A Utilisation therapeutique d'acylglycerols et de leurs analogues azotes et sulfures
FR2850869B1 (fr) * 2003-02-12 2005-03-25 Genfit S A Utilisations d'aminopropanediols acyles et de leurs analogues azotes et sulfures
JP2006519229A (ja) 2003-02-13 2006-08-24 アルバート・アインシュタイン・カレッジ・オヴ・メディシン・オヴ・イェシヴァ・ユニヴァーシティ 視床下部内の長鎖脂肪アシルＣｏＡレベルの変調による摂食量およびグルコース産生量の調節
EP1718602A4 (en) * 2004-01-30 2007-12-12 Peplin Biolipids Pty Ltd THERAPEUTIC AND CARRIER MOLECULES
US8137994B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US8137993B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US20050215558A1 (en) * 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
CA2566723A1 (en) * 2004-05-28 2005-12-15 Janssen Pharmaceutica N.V. New intravenous drug administration and blood sampling model in the awake rat
DE102004034640A1 (de) 2004-07-16 2006-02-16 Institut für Molekular- und Systemmedizin Verfahren zur systemischen Biokorrektur eines Organismus
NO324534B1 (no) * 2004-07-19 2007-11-19 Thia Medica As Materiale fremstilt fra en kombinasjon av ikke-β-oksiderbare fettsyreanaloger og en planteolje eller fiskeolje samt anvendelser derav
KR20070054637A (ko) * 2004-07-19 2007-05-29 티아 메디카 에이에스 식물유 및/또는 어유 및 비-산화성 지방산 구성요소를포함하는 조성물
WO2006041922A2 (en) * 2004-10-08 2006-04-20 Dara Biosciences, Inc. Agents and methods for administration to the central nervous system
WO2006083439A2 (en) * 2004-12-28 2006-08-10 The Research Foundation Of State University Of New York At Buffalo Method for lowering serum homocysteine
US20070026079A1 (en) * 2005-02-14 2007-02-01 Louis Herlands Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels
EP1888727B1 (en) 2005-05-04 2015-04-15 Pronova BioPharma Norge AS New dha derivatives and their use as medicaments
US7586003B2 (en) * 2005-07-14 2009-09-08 Zinpro Corporation Derivatives of seleno-amino acids
NO20053519L (no) * 2005-07-18 2007-01-19 Thia Medica As Anvendelse av forbindelser som omfatter fettsyrer
NO20055541L (no) * 2005-11-23 2007-05-24 Berge Biomed As Use of fatty acid analogues
GB0605900D0 (en) * 2006-03-23 2006-05-03 Lipigen As Modulators of nuclear receptors
US20080085293A1 (en) * 2006-08-22 2008-04-10 Jenchen Yang Drug eluting stent and therapeutic methods using c-Jun N-terminal kinase inhibitor
CA2666846C (en) 2006-10-20 2018-04-10 Cpd, Llc Method of restoring the incretin effect
CN101535238A (zh) * 2006-11-01 2009-09-16 普罗诺瓦生物医药挪威公司 作为过氧化物酶体增生物激活受体(PPAR)的活化剂或调节剂的α-取代的ω-3脂质
EP2129646A2 (en) * 2006-11-01 2009-12-09 Pronova Biopharma Norge AS Omega-3 lipid compounds
WO2008106092A1 (en) * 2007-02-26 2008-09-04 Yeda Research And Development Co. Ltd. Enantiomers of amino-phenyl-acetic acid octadec- 9- (z) enyl ester, their salts and their uses
US20080221115A1 (en) * 2007-02-26 2008-09-11 Liat Hayardeny-Nisimov Use of long-chain alcohol derivatives for the treatment of alopecia areata
EP2214481B1 (en) 2007-10-15 2019-05-01 United Animal Health, Inc. Method for increasing performance of offspring
EP2217558A1 (en) * 2007-10-31 2010-08-18 Pronova Biopharma Norge AS New dha derivatives and their use as medicaments
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
JP5373888B2 (ja) * 2008-04-29 2013-12-18 エフ．ホフマン−ラ ロシュ アーゲー Ｃｐｔ２インヒビターとしての４−トリメチルアンモニオ−ブチラート類
EP2147910A1 (en) * 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Novel lipid compounds
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
US8650937B2 (en) 2008-09-19 2014-02-18 Tandem Diabetes Care, Inc. Solute concentration measurement device and related methods
JP5843755B2 (ja) 2009-05-08 2016-01-13 プロノヴァ・バイオファーマ・ノルゲ・アーエスＰｒｏｎｏｖａ ＢｉｏＰｈａｒｍａ Ｎｏｒｇｅ ＡＳ 心血管性、代謝性および炎症性疾患領域に関する疾患の処置のための多価不飽和脂肪酸
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
EP2724739B1 (en) 2009-07-30 2015-07-01 Tandem Diabetes Care, Inc. Portable infusion pump system
US20120028335A1 (en) 2010-07-28 2012-02-02 Life Technologies Corporation Anti-viral azide-containing compounds
US20130209550A1 (en) 2010-07-28 2013-08-15 Life Technologies Corporation Anti-Viral Azide Containing Compounds
SG190114A1 (en) 2010-11-05 2013-07-31 Pronova Biopharma Norge As Methods of treatment using lipid compounds
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
MX2015011074A (es) 2013-02-28 2016-03-09 Pronova Biopharma Norge As Composicion que comprende un compuesto lipido, un triglicerido y un tensioactivo, y metodos de uso de la misma.
EP2968568A2 (en) 2013-03-11 2016-01-20 Life Science Nutrition AS Natural lipids containing non-oxidizable fatty acids
US10154979B2 (en) 2013-03-11 2018-12-18 Sciadonics, Inc. Lipid compositions containing bioactive fatty acids
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
RU2522224C1 (ru) * 2013-08-06 2014-07-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Уральская государственная академия ветеринарной медицины" Способ лечения острого гепатоза у кошек
ES2787223T3 (es) 2014-11-07 2020-10-15 Univ Minnesota Sales y composiciones útiles para tratar enfermedades
JP6784696B2 (ja) 2015-04-28 2020-11-11 プロノヴァ バイオファーマ ノルゲ エーエス 硫黄を含有する構造的に強化された脂肪酸の非アルコール性脂肪性肝炎の予防及び／又は治療のための使用
US10492141B2 (en) 2015-11-17 2019-11-26 Tandem Diabetes Care, Inc. Methods for reduction of battery usage in ambulatory infusion pumps
US10792266B2 (en) 2017-10-23 2020-10-06 Epitracker, Inc. Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome
KR20200096791A (ko) 2017-12-06 2020-08-13 바스프 에이에스 비알콜성 지방간염 치료용 지방산 유도체
EP3934639A4 (en) * 2019-03-04 2023-01-11 Epitracker, Inc. FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE DISORDERS, BEHAVIORAL DISORDERS AND CHRONIC PAIN

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59175425A (ja) * 1983-03-25 1984-10-04 Otsuka Pharmaceut Co Ltd 脳卒中予防剤
GB8813012D0 (en) * 1988-06-02 1988-07-06 Norsk Hydro As Non-b-oxidizable fatty acid analogues to reduce concentration of cholesterol & triglycerides in blood of mammals
US6063581A (en) * 1992-01-22 2000-05-16 Axis-Shield Asa Immunoassay for homocysteine
WO1996040098A2 (en) * 1995-06-07 1996-12-19 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
NO952796D0 (no) * 1995-07-14 1995-07-14 Rolf Berge Fettsyre analoger med ikkeoksyderbart B-sete, fremstilling og anvendelse i krapeutiske preparater
DE69622722T2 (de) * 1996-11-20 2003-02-27 Nutricia Nv Fette enthaltende Ernährungszusammensetzung zur Behandlung des Stoffwechselsyndroms
WO1999058120A1 (en) * 1998-05-08 1999-11-18 Rolf Berge USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS

Also Published As

Publication number Publication date
NO20005462L (no) 2001-01-08
WO1999058121A1 (en) 1999-11-18
EP1075259A1 (en) 2001-02-14
EP1075258A1 (en) 2001-02-14
KR20010043316A (ko) 2001-05-25
DK1075260T3 (da) 2006-02-06
CN1300212A (zh) 2001-06-20
NO20005463L (no) 2001-01-08
US6365628B1 (en) 2002-04-02
DE69909775D1 (de) 2003-08-28
KR20010043315A (ko) 2001-05-25
ATE247464T1 (de) 2003-09-15
AU761355B2 (en) 2003-06-05
RU2219920C2 (ru) 2003-12-27
CN1245157C (zh) 2006-03-15
CA2331393C (en) 2009-08-11
DE69909775T2 (de) 2004-06-03
NZ508046A (en) 2003-08-29
DE69927805T2 (de) 2006-07-06
NZ508047A (en) 2003-05-30
ATE245416T1 (de) 2003-08-15
JP2002514596A (ja) 2002-05-21
AU4936799A (en) 1999-11-29
US7026356B2 (en) 2006-04-11
HK1034911A1 (en) 2001-11-09
NO20005463D0 (no) 2000-10-30
ES2251218T3 (es) 2006-04-16
AU7240398A (en) 1999-11-29
JP5057003B2 (ja) 2012-10-24
EP1285652B1 (en) 2006-08-16
WO1999058122A1 (en) 1999-11-18
RU2221558C2 (ru) 2004-01-20
US20020198259A1 (en) 2002-12-26
PT1075259E (pt) 2003-12-31
US6441036B1 (en) 2002-08-27
DE69932645D1 (de) 2006-09-14
NO333143B1 (no) 2013-03-18
AU4936699A (en) 1999-11-29
NO20005461D0 (no) 2000-10-30
JP4465672B2 (ja) 2010-05-19
CA2331395C (en) 2008-10-14
CN1302204A (zh) 2001-07-04
EP1285652A1 (en) 2003-02-26
CA2331395A1 (en) 1999-11-18
EP1075260A2 (en) 2001-02-14
ES2204142T3 (es) 2004-04-16
JP2002514595A (ja) 2002-05-21
ATE336239T1 (de) 2006-09-15
CA2331393A1 (en) 1999-11-18
KR100822077B1 (ko) 2008-04-14
EP1075260B1 (en) 2005-10-19
DE69932864D1 (de) 2006-09-28
BR9910297A (pt) 2002-01-02
DE69910559T2 (de) 2004-06-17
CN1223343C (zh) 2005-10-19
EP1284139A1 (en) 2003-02-19
CN1244323C (zh) 2006-03-08
HK1034912A1 (en) 2001-11-09
NO20005461L (no) 2001-01-08
DE69927805D1 (de) 2006-03-02
AU5451799A (en) 1999-11-29
CA2331408C (en) 2008-10-21
WO1999058123A2 (en) 1999-11-18
BR9910296A (pt) 2002-01-15
US6417232B1 (en) 2002-07-09
JP2002514594A (ja) 2002-05-21
EP1075258B1 (en) 2003-08-20
AU762790B2 (en) 2003-07-03
HK1034909A1 (en) 2001-11-09
WO1999058123A3 (en) 2000-03-09
RU2223095C2 (ru) 2004-02-10
DE69910559D1 (de) 2003-09-25
CA2331408A1 (en) 1999-11-18
WO1999058120A1 (en) 1999-11-18
AU762792B2 (en) 2003-07-03
DK1075259T3 (da) 2003-11-03
PT1075258E (pt) 2004-01-30
KR100701503B1 (ko) 2007-04-02
EP1075259B1 (en) 2003-07-23
CN1300211A (zh) 2001-06-20
ATE306916T1 (de) 2005-11-15
NZ508045A (en) 2003-08-29
KR20010043314A (ko) 2001-05-25
NO20005462D0 (no) 2000-10-30
ATE334666T1 (de) 2006-08-15
ES2207253T3 (es) 2004-05-16
KR100701502B1 (ko) 2007-04-02
EP1284139B1 (en) 2006-08-02

Similar Documents

Publication Publication Date Title
DK1075258T3 (da) Hidtil ukendte fedtsyreanaloger til behandling af adipositas
AU2721402A (en) Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto
BR0113162A (pt) Ariloxialquilaminas nao-imidazóis
DK1485359T3 (da) Natriumkanalblokkere
DK1144365T3 (da) Inhibitorer af alfa4beta1-medieret celleadhæsion
ATE354622T1 (de) Flüssigkristallines medium
ATE224385T1 (de) Kristallmodifikation der liponsäure
BR0212899A (pt) Compostos orgânicos
TR200201128T2 (tr) PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri.
AU2003294092A1 (en) Derivatives of indole-3-carboxamide, preparation method thereof and application of same in therapeutics
DK1204659T3 (da) Serotonerge benzofuraner
TR199903159T2 (xx) Yeni �-Amino ve �-Azido karbonik asit t�revleri.
DK1392672T3 (da) Chlormethylering af thiopen
DE59803066D1 (de) Substituierte benzyloxyimino-verbindungen
DK1144553T3 (da) Benzinstabiliserende sammensætning til forhindring af gummidannelse
YU70799A (sh) Derivati tiazofurina